TW202104228A - 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物 - Google Patents

用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物 Download PDF

Info

Publication number
TW202104228A
TW202104228A TW109112257A TW109112257A TW202104228A TW 202104228 A TW202104228 A TW 202104228A TW 109112257 A TW109112257 A TW 109112257A TW 109112257 A TW109112257 A TW 109112257A TW 202104228 A TW202104228 A TW 202104228A
Authority
TW
Taiwan
Prior art keywords
compound
polymer
amorphous
dispersion
sdd
Prior art date
Application number
TW109112257A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 Ｊ 加爾麥斯
傑奎恩 卡拉尼 李凡斯
傑 普爾納 雷迪
凱文 Ｊ 史迪方斯基
威魯夏里 Ｍ 瓦克尼斯
特瑞莎 Ｍ 杰姆巴
阿杰 薩克森納
斯里坎特 克拉瓦第 斯里達爾
加金德拉 辛格 查望
沙密斯達 帕勒
沙必拉里 怕達瑟里
璐帕 那拉辛哈姆帝
娜拉言 史瓦米 潘度蘭卡
Original Assignee
美商必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商必治妥美雅史谷比公司 filed Critical 美商必治妥美雅史谷比公司
Publication of TW202104228A publication Critical patent/TW202104228A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109112257A 2019-04-11 2020-04-10 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物 TW202104228A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
US62/832,606 2019-04-11

Publications (1)

Publication Number Publication Date
TW202104228A true TW202104228A (zh) 2021-02-01

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109112257A TW202104228A (zh) 2019-04-11 2020-04-10 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物

Country Status (18)

Country Link
US (2) US12509461B2 (https=)
EP (1) EP3953355A1 (https=)
JP (2) JP2022526656A (https=)
KR (1) KR20210151183A (https=)
CN (1) CN113924300A (https=)
AR (1) AR118650A1 (https=)
AU (2) AU2020271103B2 (https=)
BR (1) BR112021020257A2 (https=)
CA (1) CA3132530A1 (https=)
CL (1) CL2021002627A1 (https=)
CO (1) CO2021015054A2 (https=)
EA (1) EA202192753A1 (https=)
IL (1) IL287103A (https=)
MX (2) MX2021012288A (https=)
PE (1) PE20212367A1 (https=)
SG (1) SG11202111131VA (https=)
TW (1) TW202104228A (https=)
WO (1) WO2020210629A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023010629A (es) 2021-03-09 2023-09-19 Bayer Ag Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida.
TW202327607A (zh) 2021-09-17 2023-07-16 美商必治妥美雅史谷比公司 用於預防及治療血管栓塞病症之米爾維仙(milvexian)
UY40381A (es) 2022-08-01 2024-01-31 Janssen Pharmaceutica Nv Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico
CN120712076A (zh) 2023-02-06 2025-09-26 百时美施贵宝公司 米尔维仙药物组合物
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569786A (da) 1985-11-27 1987-05-28 Syntex Inc Benzimidazolderivater
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
KR101739994B1 (ko) * 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
CN116987080A (zh) * 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (https=) * 2014-10-01 2018-10-20
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
PT3445767T (pt) 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro

Also Published As

Publication number Publication date
AU2020271103A1 (en) 2021-12-02
IL287103A (en) 2021-12-01
US20220144835A1 (en) 2022-05-12
US20260042761A1 (en) 2026-02-12
AU2020271103B2 (en) 2026-01-08
WO2020210629A1 (en) 2020-10-15
AU2025279715A1 (en) 2026-01-15
AR118650A1 (es) 2021-10-20
PE20212367A1 (es) 2021-12-21
MX2025011559A (es) 2025-11-03
SG11202111131VA (en) 2021-11-29
JP2022526656A (ja) 2022-05-25
US12509461B2 (en) 2025-12-30
JP2025131625A (ja) 2025-09-09
EP3953355A1 (en) 2022-02-16
EA202192753A1 (ru) 2022-01-11
CO2021015054A2 (es) 2021-11-19
MX2021012288A (es) 2021-11-12
CA3132530A1 (en) 2020-10-15
CL2021002627A1 (es) 2022-05-06
BR112021020257A2 (pt) 2021-12-07
KR20210151183A (ko) 2021-12-13
CN113924300A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
TW202104228A (zh) 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
JP7469304B2 (ja) Ｐａｒｐインヒビタを含む医薬組成物
CA3019257C (en) A pharmaceutical formulation of palbociclib and a preparation method thereof
CN108938583B (zh) 包含无定形达格列净的制剂
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
CN101267810A (zh) 吡非尼酮与药物可接受的赋型剂的胶囊制剂
WO2022141665A1 (zh) 一种水溶性大麻素制剂及其制备方法
US5906991A (en) Process for the manufacture of flavanolignan preparations with improved release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals
TWI908789B (zh) 固形製劑及其製造方法
CN105732517A (zh) 包含烟酰胺为前驱体的5-氟尿嘧啶药物共晶的药物制剂及其制备方法
KR20120121944A (ko) 안정성이 개선된 리마프로스트 함유 약제학적 조성물 및 이의 제조방법
EA052985B1 (ru) Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме
EP3572069A1 (en) Increasing solubility and bioavailability of enzalutamide
KR100432949B1 (ko) 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
CN116898852A (zh) 一种氧代哒嗪酰胺类衍生物的药物组合物及其制备方法与医药用途
EP4251271A1 (en) Direct compression method for non-micronised apixaban formulations
HK40025159B (en) Orally administrable enzalutamide-containing pharmaceutical composition
JP2002302443A (ja) シンバスタチン含有製剤
HK40025159A (en) Orally administrable enzalutamide-containing pharmaceutical composition
Hemanth Preparation and evaluation of solid dispersions of pioglitazone
HK40004093A (en) Pharmaceutical preparation of palbociclib and preparation method thereof
KR20050115355A (ko) 이트라코나졸 함유 조성물 및 그의 제조방법